Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, which is a New Chemical Entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!